| Schedule of Cash and Cash Equivalents |
The
following table provides a reconciliation of cash and restricted cash reported within the balance sheet dates that comprise the total
of the same such amounts shown in the unaudited condensed consolidated statements of cash flows (in thousands):
Schedule of Cash and Cash Equivalents
| | |
June 30, 2026 | | |
June 30, 2025 | |
| Cash | |
$ | 4,071 | | |
$ | 5,279 | |
| Restricted cash included within prepaid expenses and other current assets | |
| 219 | | |
| 100 | |
| Total cash and restricted cash as shown in the unaudited condensed consolidated statements of cash flows | |
$ | 4,290 | | |
$ | 5,379 | |
|
| Schedule of Computation of Diluted Net Loss per Common Share including Antidilutive |
As
a result of the Company reporting net loss attributable to common stockholders for all periods presented herein, the following common
stock equivalents were excluded from the computation of diluted net loss per common share for the six months ended June 30, 2026 and
2025 because including them would have been antidilutive:
Schedule
of Computation of Diluted Net Loss per Common Share including Antidilutive
| | |
2026 | | |
2025 | |
| | |
Six Months Ended June 30, | |
| | |
2026 | | |
2025 | |
| Warrants for common stock | |
| 2,619,735 | | |
| 87,750 | |
| Employee stock options | |
| 16,798 | | |
| 8,167 | |
| Restricted stock units | |
| 75 | | |
| — | |
| Earnout shares | |
| 9,375 | | |
| 9,375 | |
| Total common stock equivalents | |
| 2,645,983 | | |
| 105,292 | |
|
| Schedule of Operating Segment |
The
following table presents selected financial information with respect to the Company’s single operating segment for the three and
six months ended June 30, 2026 and 2025:
Schedule
of Operating Segment
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three Months Ended June 30, | | |
Six Months Ended
June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| OPERATING EXPENSES | |
| | | |
| | | |
| | | |
| | |
| Salaries and benefits | |
$ | 1,654 | | |
$ | 2,957 | | |
$ | 3,354 | | |
$ | 5,147 | |
| Insurance | |
| 186 | | |
| 238 | | |
| 367 | | |
| 474 | |
| Legal | |
| 155 | | |
| 350 | | |
| 419 | | |
| 649 | |
| Consulting | |
| 355 | | |
| 592 | | |
| 639 | | |
| 1,211 | |
| Rent and Maintenance | |
| 245 | | |
| 610 | | |
| 812 | | |
| 1,175 | |
| Clinical & research and development | |
| 1,028 | | |
| 427 | | |
| 1,802 | | |
| 890 | |
| Depreciation expense | |
| 89 | | |
| 96 | | |
| 176 | | |
| 187 | |
| Other operating expense (1) | |
| 438 | | |
| 394 | | |
| 768 | | |
| 993 | |
| Total
operating expenses | |
| 4,150 | | |
| 5,664 | | |
| 8,337 | | |
| 10,726 | |
| Loss
from operations | |
| (4,150 | ) | |
| (5,664 | ) | |
| (8,337 | ) | |
| (10,726 | ) |
| OTHER INCOME
(EXPENSE), NET | |
| | | |
| | | |
| | | |
| | |
| Change in fair value of other liabilities and derivatives | |
| (1 | ) | |
| (19 | ) | |
| 47 | | |
| 16 | |
| Other non-operating income (expense),net (2) | |
| (4 | ) | |
| (74 | ) | |
| 31 | | |
| (106 | ) |
| Income tax provision | |
| (5 | ) | |
| (4 | ) | |
| (9 | ) | |
| (7 | ) |
| NET LOSS | |
$ | (4,160 | ) | |
$ | (5,761 | ) | |
$ | (8,268 | ) | |
$ | (10,823 | ) |
| |
(1) |
Other operating expense includes office expenses and marketing expenses. |
| |
(2) |
Other
non-operating income (expense), net includes interest expense, grant income and other income
(expense), net. |
|